<span item_type="fundamental" item_id="700fcfcf645f192a29842053a0814a22" counter_id="ST/US/DMAAR" env="prod"></span><span item_type="announcement" item_id="518297578643984385" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD 0.05.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not commenced any operations and does not expect to generate operating revenues until after the completion of its initial Business Combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Net income for the three months ended March 31, 2025, was $1,254,543, primarily due to interest earned on cash and investments held in the Trust Account amounting to $1,585,468, offset by general and administrative costs of $330,925.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the three months ended March 31, 2025, was - $251,244.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li>Net cash used in investing activities was - $231,150,000, primarily due to investment of cash into the Trust Account.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li>Net cash provided by financing activities was $231,400,816, mainly from proceeds from the sale of Units and Private Placement Units.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company has placed $231,150,000 in a Trust Account from the net proceeds of the Initial Public Offering and Private Placement Units.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company intends to focus on companies in the pharmaceutical industry for its Business Combination. It has up to 15 months from the closing of the Initial Public Offering to complete a Business Combination, which can be extended up to 21 months.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li><strong>Non-Core Business</strong>: The company is a blank check company and has not commenced any operations. It is focused on identifying a target company for a Business Combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li><li><strong>Priority</strong>: The company plans to use the funds from the Trust Account to complete its initial Business Combination, with the possibility of extending the period to complete the Business Combination by depositing additional funds into the Trust Account.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2028614/000121390025046061/ea0242665-10q_drugs.htm"></span></li></ul>

DRUGS MADE IN AMER ACQUISITION CORP COM USD0.0001 15/10/2029 (SUB/RIGHTS) | 10-Q: FY2025 Q1 EPS: USD 0.05